Special Issue "Neuroprotective Agents"
Deadline for manuscript submissions: 30 December 2017
Prof. Dr. Jia Zhou
Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA
Website1 | Website2 | E-Mail
Interests: drug discovery; target-based drug design; fragment/structure-based drug design; pharmacological tools; CNS therapeutics; neuroprotective agents; anticancer agents; anti-inflammatory agents; antiviral agents; drug development; chemical biology
Neuroprotection represents one of the most appealing therapeutic strategies for preventing neurodegeneration and mitigating against neuronal damage. The development of novel neuroprotective agents has attracted tremendous drug discovery efforts, with the aim of identifying effective neurotherapeutics for a variety of central nervous system (CNS) disorders, including neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), dementia, stroke, traumatic brain injury (TBI), spinal cord injury, schizophrenia, drug abuse-induced neurotoxicity (i.e. methamphetamine overdoses), and even retinal diseases and glaucoma. This Special Issue aims to provide a forum for the dissemination of the latest information on new molecules including both synthetic compounds and natural products as well as novel drug targets associated with neuroprotective agents. As the Guest Editor, I would like to thank all the authors for their tremendous effort, dedication, and excellent contribution to this special issue of Neuroprotective Agents. I hope that this issue will serve as a key reference work for medicinal chemists, chemical biologists, neuropharmacologists, and other research investigators engaged in or interested in neuroprotection and neuroprotective agent drug discovery and development.Prof. Dr. Jia Zhou
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- neuroprotective agents
- neuroprotective drugs
- neuronal cell death
- drug discovery and development
- synthetic molecules
- natural products
- drug targets and mechanisms
- central nervous system (CNS) disorders
- neurodegenerative diseases
- Alzheimer's disease (AD)
- Parkinson's disease (PD)
- amyotrophic lateral sclerosis (ALS)
- traumatic brain injury (TBI)
- spinal cord injury
- drug abuse-induced neurotoxicity (i.e. methamphetamine overdoses)
- retinal diseases and glaucoma